Abstract
Introduction
Public authorities have recently supported development of the biotechnology sector by encouraging start-ups and creating favourable environments such as incubators, a specialised stock exchange or technopoles. The different programmes to encourage biotech development (P. Monsan, 1999 ) (subsidies for research performed jointly by firms and academic labs, subsidies for start-ups, creation of incubators) seem to be successful if the results are estimated in terms of the number of new firms (around 300 SMEs still in existence, since 1990 1 ). On 1 January 1999 France had just over 400 biotechnology SMEs employing a total of 15,000 people, with an estimated turnover of 2 billion euros 2 .
Estimates based on the survey initiated by the MENRT * are consistent with information published by Ernst and Young, although they indicate a higher number of firms in France.
Average size in terms of number of employees per firm is nevertheless similar: about 40
persons, compared to about 140 in USA. All in all, biotechnology remains a small emergent sector compared to others such as agri-food (over 4,200 French firms with 372,300 employees and a turnover of 100 billion euros) or pharmaceuticals (94,500 employees in 271 firms and a turnover of 28,5 billion euros 3 ).
1 As the mortality rate is high, our figure under-estimates the number of firms set up during the last 10 years.
But it gives an idea of the number of firms set up and which survive. 2 This figure does not take into account divisions in certain firms specialised in biotechnology, with over 500 employees. * The creation of many start-ups during the past ten years raises questions on the future of biotech SMEs in France and in Europe. How will consolidation of the sector occur? Will maturity of the sector be accompanied by progressive disappearance of SMEs and the growth of firms? Will it be structured like the automobile industry, around collaboration between firms with a high capacity for integration of research performed elsewhere, and specialized firms such as parts manufacturers? What will the future be of the hundreds of small firms which focus on the local market or a specific technology, and which have grown at a moderate pace over the past ten years?
To answer these questions we have chosen to reason in terms of business models, that is, organisational models covering the targeted market (final or intermediate market), networks of partners, and shareholders. A business model corresponds to a set of key resources for the firm's development and to a mode of securing these resources within the organisation. It provides insight into the development logic of biotechnology SMEs in
France.
The aim of this paper, based on the results of a 1999 survey on all biotech SMEs in France is to understand the development logics of these firms. The first part defines the concept of a business model. The second part is an overview of biotech firms in France and their development, based of the survey carried out in 1999. It presents three business models for biotech SMEs. The third part is an attempt to map out the development trajectories of SMEs and the respective leading forces in each type of firm. Concluding remarks present three possible scenarios for the evolution of the sector.
ORGANISATION OF FIRMS AND BUSINESS MODELS

Business model as an Archetype
The formal and informal structures of firms and their external linkages have an important bearing on the firm's growth rate. According to Teece (D. J. Teece, 1996) , firms' distinctive modes of governance depend primarily on their boundaries, formal internal structure, informal structure and external relations. Rather than specifying all possible combinations, we have chosen to reason in terms of archetypes.
Greenwood and Hinings (R. Greenwood and C. R. Hinings, 1993) Ranson, C. R. Hinings and R. Greenwood, 1980) emphasise that it is necessary to investigate the social mechanisms which determine the structuring process and shape the ensuing structural forms if we are to fully understand the formation of organisational structures. One of the dimensions that has been identified to study architectural practices is motives for work, i.e. an intellectual ethos, a set of ideas about the architecture, that results in a particular set of organisational arrangements. A similar idea has been developed in Karpik's conception of a 'logic of action' and in Callon and Vignolle's notion of 'forms of coherence' (M. Callon and J. Vignolle, 1976) .
High-tech SMEs are created around a sound project supported by the creators. This project strongly structures the resources and competencies that the firms will have to mobilise.
Mobilising resources to innovate
While research on strategy has traditionally focused on an analysis of competition (M. Porter, 1980) , analysis in terms of resources and competencies has been developing since the mid-1980s. This change reflects the shift of interest from external towards internal analysis:
organisations are studied from within rather than in relation to their environment. The increasing openness of organisations has gone hand in hand with a relative disappearance of boundaries. Thus, the theory of resources, for which the definition of boundaries is less fundamental than it is for approaches focused on competition, seems particularly rich. It proposes an analysis of the organisation and of its competitive advantages in terms of tangible and intangible resources and competencies (J. B. Barney, 1991; J. B. Barney, J. C. Spender and T. Reve, 1994; R. Grant, 1991; G. Hamel, 1991 Tolbert, 1985; A. Valette, 1994; K. Weick, 1979) In the biotechnology sector, several authors have analysed firms' strategies for acquiring and stabilising the resources needed for their business and growth. G and A Eliasson (G. Eliasson, Eliasson, A., 1996) point out the differences of the biotechnology sector compared to other industrial sectors:
(1) Biotechnology is a sector that stems from academic research. Technically, the differences between an academic and a private laboratory are small. However, competencies involved in implementation and industrialisation differ substantially.
(2) The main costs are those of research and commercialisation; production costs are relatively low. To understand the logics underpinning the creation and development of biotechnology firms in France, the firms in our sample can be positioned in relation to the different dimensions defined by G. and A. Eliasson :
-Following the article by A. Nilsson (A. Nilsson, 2000) , two models of firms are identified. In the first, firms have integrated all functions, including commercialisation and marketing. These firms cater for final consumers, to whom they supply agri-food, cosmetic or pharmaceutical products. In the second model, biotech firms supply intermediary products which are integrated into the production processes of firms directly in contact with consumers. In our study, consumers' competencies were identified in this way.
-Industrialists and venture capitalists have a similar role. They help to finance firms by providing capital. They also link the firm, initially based on a scientific idea, to the business world. This connection has several forms: contact with potential industrial or commercial partners; opening of a market, particularly that of the parent company or other firms in the group, advice and support in strategic management (see Nature Biotechnol N°17, Supplement on Bioentrepreneurship, May 1999).
- Liebeskind et al. (J. P. Liebeskind et al., 1996) Armstrong, 1994) show that 97% of star scientists work in universities or non-profit research institutes. Only 3% work in enterprise.
-Even though star scientists do not work directly in biotech firms, these firms do have strong links with the academic world. Dedicated Biotech Firms (DBFs) are thus forced to develop organisational arrangements that give them access to external intellectual resources. The essential character of external resources is threefold:
(1) Relations with the academic world enables firms to explore a wide variety of hypotheses while maintaining a large degree of flexibility. Thus, exploration of scientific hypotheses in other organisations enables them to reduce costs and to avoid sunk costs, but still to be the first to benefit from the discovery.
(2) Powell (W. W. Powell, 1990) argues that social networks are the most efficient organisational arrangement for sourcing information because information is difficult to price (in a market) and to communicate through a hierarchical structure. Social networks serve as sources of reliable information, which is essential to efficient organisational learning. When knowledge is distributed among several organisations, not only access to information but also learning how to work in partnership become key variables in competition (W. W. Powell, Koput, K.W., Smith-Doerr, L., 1996; B.
L. Simonin, 1997) .
(3) Relations with the academic world, via the social networks in which the creators of the firm are involved, enable the firm to have access to unique scientific expertise that is a critical resource for its survival and development.
To sum up, the hypothesis tested in this article is that French biotech SMEs can be described in terms of a limited number of business models structured by the way in which these DBFs mobilise competencies in order to innovate.
DATA AND METHODS
Biotechnology: a small industrial sector
The French biotechnology sector is an emergent sector consisting of about 400 small businesses in widely diverse markets. 221 firms responded to our survey conducted in the avr00.doc 07/02/06 first half of 1999. 186 complete answers were processed. (See box for the detailed methodology of the survey.)
Firms that do customised work for companies in direct contact with consumers
Like everywhere else, French DBFs have little contact with the end user. Only 12% of firms have such contact (mainly for agri-food products, cosmetics and, to a lesser degree, human health). 88% of biotech firms are active suppliers of intermediary goods and services for other firms in the fields of human or animal health, cosmetics, environment or agri-food.
As shown in Table 1 , the majority of biotech SMEs specialise in the design, development and production of customised genetic or biological material. A small minority (20%) is engaged in product development (human health -8% and other, apart from drugs -12%).
Most firms are service providers. They sell biological material to companies in all sectors, enabling them to produce either more quickly or better quality products (e.g. more standardised and better controlled quality), at a lower cost. 48% of firms produce goods, 18% supply products and services and 34% provide services only.
Insert table 1 here
The activity of biotechnology firms is described in relation to two dimensions: the business sector in which the firm sells its products or services, and the company's core competencies (or speciality). The sectors in which it sells its products or services are described in the following way:
-The firm caters for a sector: agriculture or the agri-food industries (26%), cosmetics (4%) or pharmaceuticals (37%).
-The firm commercialises its products and services in two sectors which do not require a marketing license: agriculture/agri-food and cosmetics (1%).
-The firm generates a cash flow from the sale of products and services in the cosmetic or agri-food sector and carries out research in the human health sector -a sector in which it takes longer to generate turnover (12%).
-The firm has generic know-how which it uses in all sectors (equipment, materials, etc.) (21%).
avr00.doc 07/02/06
The core competencies of the firm describes the products and services that it designs, produces and markets. Four categories have been identified: -Product development (20%). The firm's business is production and marketing of products. It does not produce customised products only; it also mass produces.
-Diagnosis and creation of tests and/or biological material (55%). These firms develop two complementary activities: a) as service providers to other companies they create tests, biological material with specific characteristics, and customised diagnoses; and b) they design, produce and commercialise diagnostic kits, either directly or through other companies.
-Design and production of equipment and material for laboratories. These firms cater for all sectors. They account for 9% of the total.
-Development aid methods or sequencing. These firms design methods enabling firms to improve their processes or to market their products more effectively (e.g. CRO 4 ).
These firms, which account for 17% of the total, cater primarily for the pharmaceutical and agri-food sectors.
To sum up, out of the firms active in the human health sector, few are directly engaged in the production of drugs. Firms in the agriculture, agri-food or environment fields produce mainly seeds or foods with specific characteristics (health or functional food). Service firms in these sectors mainly provide tests or diagnostic kits for agriculture or agri-food and the environment. SMEs focused on the cosmetic or animal health sectors have largely the same characteristics: close to firms in the human health field, they develop products or services which do not require specific marketing licenses. This market positioning often corresponds to a strategy for progressively conquering the human health market.
Firms active in all the sectors are mainly those which design and develop generic tools or methods (such as sequencing or instrumentation).
Mainly new DBFs
Close to 70% of firms which were still alive in 1999 had been founded after 1990. Firms that are 20 years old or more now account for 12% of the sample, while the most recent firms account for 69% of the total. Less than 20% of all firms were created between 1980 and 1990.
Insert table 2 here
The average number of employees of an DBF is 37 persons, for an average turnover of 480 KE * . Whether in terms of turnover or number of employees, these firms remain small. 72% have a turnover under 1.5 ME ** , compared to only 4% with over 15 ME. 24% have a turnover between 1.5 and 15 ME. Moreover, 55% employ fewer than 10 persons and only 14% employ over 50 persons. 31% employ between 10 and 50 persons. and 1990 grew more slowly.
Firms active in the agro-food or agronomic sectors and those which are active in the pharmaceutical sector are larger than the others in terms of number of employees. Business creation was spread out over time, and across all sectors equally.
BUSINESS MODELS
To understand the growth of firms and the dynamics in which they are engaged, we chose to reason in terms of business models. A business model describes a category of firm in relation to the market it targets, its expected growth and the organisation of its activity. The biotech firms which responded to our survey are spread out in the following way, in terms of criteria borrowed from Eliasson:
Insert table 3 here
The four dimensions proposed, following G. and A. Eliasson, enable us to define three business models structured around management of industrial property, networks of shareholders, and the firm's position in the market. 
Insert table 4 here
We can thus identify four groups of firm, the characteristics of which are given in Tables 5   and 6 1994) . These contracts are one of the ways of getting round barriers to entry, on both a scientific and a commercial level. They also enable these firms to benefit from faster learning and to acquire additional competencies.
Group B : Firms which develop in niches
These firms all started with the idea of an entrepreneur who mobilised family capital (60% of the firms have only natural persons as shareholders). Very few of them have venture capital firms or other firms among their shareholders. They have little capital and generate turnover from the outset, especially through customised production or service provision.
Their turnover is substantially lower (under 1.5 ME) than that of other types of firm. They rarely develop an activity which caters specifically for pharmaceutical companies. On the other hand, they have a strong presence in the agriculture and agri-food fields. They rarely patent their technology although they sell their products to final consumers. These firms look in their immediate environment -family and geographic -for catching the resources to survive and grow. Often they have very few links to networks of actors active in biotechnology (consulting firms, venture capital firms, academics or recognised researchers, ANVAR, ministries, etc.). Relations with the market and users of their products and services are formed on the basis of geographic proximity. They grow as they expand their clientele beyond the local market, by broadening the range of their services or specialising their supply so that they become the leader in their market.
Group C : Firms attached to a group
The capital of firms in this group is mainly in the hands of natural persons and other firms.
Venture capital is seldom present in firms in this group 5 . Either they were bought out when they were independent, or they were created directly by their parent company. In fact, one of the strategies of pharmaceutical or seed companies is to create biotech firms, either alone or in partnership with other firms. Biotechnologies are a high-risk business whose development relies on specific competencies that are sometimes difficult to maintain within a group. Small structures are more flexible and adjust better than large ones to changes induced by the production of new scientific knowledge. Finally, investing in a biotech subsidiary also enables firms to set up in countries where they can take advantage of externalities of its research and of new markets. Yet firms in this group form fewer ties with academic research than others, especially with INSERM and the CNRS. It seems that the parent company or shareholding company is a special partner, including for research.
Thus, major French companies (Limagrain, Aventis, etc.) and foreign corporations (Monsanto, etc.) have invested in subsidiaries created ex nihilo and specialised in biotechnology, in order to set up in France (e.g. BioSepra, Bachem Biochimie or Diagnostica Stago) or to isolate their biotechnology activity from their core business (e.g.
Syral, Biosem or Limagrain Genetics). These firms, which benefit from the captive market of the parent company and the networks and markets to which it affords access, see their turnover increase faster than that of independent firms. Companies in this category are much bigger (in terms of number of employees) and have a significantly higher turnover than those in the other categories. This growth is based above all on the parent company's internal network. On the other hand, the fact that they patent less may not be significant, for some patents may be registered by the parent company.
Group R : New Biotech Firms (DBFs)
This group comprises firms that had been in existence for less than two years at the time of the survey. They are thus constantly evolving. Significantly smaller (Table 6 ) than firms in the other groups, in terms of number of employees and turnover (often two or three avr00.doc 07/02/06 persons, some of whom work part time), DBFs have registered few patents 6 . On the other hand, they have persuaded capital investors to become shareholders (Table 5) . Capital investors are often firms in the seed business and are often regional and multi-sectoral.
Their capital investments enable biotech firms to survive, for many of these DBFs generate no turnover. They are very seldom engaged in the production of goods for final consumers.
By contrast, they have partnerships with research organisations, especially INSERM. The youngest firms are oriented essentially towards the pharmaceutical sector. They are less present in the agriculture, agri-food and cosmetic sectors.
COMPETING BUSINESS MODELS
Three logics for three business models
The statistic analysis reveals four types of firm which were designed differently from the For these firms, often created by researchers from large groups or by academic researchers, insertion in the scientific network is a condition for growth. It is not sufficient, however, for firms must not only develop high-tech research but also transfer and commercialise their results. This often involves research or development contracts with a big company, in which the SME undertakes to provide its partner with specific materials, technologies, know-how or expertise. Relations are formed on the basis of a specific competency recognised by the big firm. The SME's technological lead depends on the quality of its avr00.doc 07/02/06 research, and the launching of the activity relies on capital input for the development of the product or process.
Firms in Group B are based on a different logic. Created by researchers or engineers who have identified a commercial opportunity, they focus on specific niches and generate turnover very soon after creation. These firms are part of a local economic fabric resulting from contracts developed by the entrepreneur during his or her previous activity.
The development logic can be outlined as follows:
Identification of a niche or idea to transfer research --> creation of a firm based on family capital --> commercialisation of products or services to generate a cash flow --> development of business by expansion of the market.
In this logic, the firm's key resources are its first customers and its regional or sectoral position which enable it to be known.
Firms in Group C rely on the group to develop their business. They progressively expand their clientele.
Competition or complementarity
Competition between firms occurs when they are present in the same market. In that case, it is the firms' products or services that compete. Given the emergent character of the biotechnology sector and the innovative nature of the services or products offered, markets are constructed along with supply. Thus, it seems that, at this stage, firms are rivals in their market segment, within the same business model. The market, as usually described, represents a key resource in the development of firms only for those belonging to Group B.
On the other hand, all firms are rivals for the acquisition and integration of key resources for development. Table 7 describes the different areas of competition. As they are based on research and most of them are financing their activities thanks to capital investments, firms on the different business models are not only competing on the markets. They are also competing to convince shareholders (and venture capitalists) to invest in their activities, to develop co-operation with established and promising academic teams (having a star scientist as a Nobel prize as a collaboration or in the scientific advisory board can boost your activity avr00.doc 07/02/06 and your share) and to contract with large firms to finance the development and the commercialisation of product.
Insert table 7 here
Resources needed by firms to grow are specific to each type of business model. Thus, firms compete within a business model. But competition between business models remains marginal, both in markets and for the acquisition of resources which, even if they are similar, are owned by different actors.
CONCLUSION
Still to be done
ANNEXES
Box: Characteristic of the survey
At the initiative of the technology division (Biotechnology group) of the MENRT 7 , a survey was conducted on firms engaged in biotechnology research or development. A questionnaire was sent to 450 private organisations, irrespective of their size or status (listed or not). 221 answers were received but they were largely incomplete. In order to obtain a representative sample, the data base thus obtained was matched with various other available data bases: the base created by the INRA/SERD team, The France Biotech base, the Genetic Engineering Directory, Infogreffe and Diane. Missing information was thus obtained and certain firms were added to the base when all necessary information was available.
In order to standardise the answers, only organisations listed in the trade and commercial register as companies (SA, SARL, SNC) were selected. To guarantee the relevance of comparisons with information published by Ernst and Young (1999 Report), our analysis took into account only those firms with under 500 employees. Lastly, we excluded the rare biotechnology firms founded before 1960. The analysis was finally based on 186 enterprises on which full information was available. The sample analysed can be considered representative, essentially because over 60% of the firms listed in the France Biotech 1998 directory and 90% of the firms in the Genetic Engineering Directory answered the questionnaire. By convention, we consider that the base analysed corresponds to roughly half of the biotechnology enterprises active in France.
The survey consisted of several steps: 1. Compilation of a list of enterprises engaged in biotechnology research, based on available sources; 2. Validation of this list compiled by regional technology representatives, and addition of complementary data; 3. Definition of a list of 450 target enterprises; 4. Administration of the questionnaire; 5. Processing of data and compilation of the directory. The survey gathered information on several dimensions: 1. Identification of the firm; 2. Ownership and creators; 3. Targeted markets and technologies in use; 4. Patents and certification; 5. Financial information; 6. Partnerships.
List of variables
Creation 1980-90 : Creation of the firm between 1980 and 1990 A : Business model "Firms with high growth potential" sh vent. K : Venture capital firm a shareholder in the SME sh pers : Shareholder a natural person sh firm : Firm a shareholder of the SME Agri/envt : Targeted sector of the firm is agriculture, agro-food or environment After 90 : Creation of the firm after 1990 Before 80 : Creation of the firm before 1980 B : Business model : Firms which develop in niches Patent : hold patents C : business model : Firms attached to a group TO 1,5 and 15 Meuros : Turnover between 1.5 and 15 ME per year TO less than 1,5 Meuros : Turnover less than 1.5 ME per year TO up to 15 Meuros : Turnover up to 15 ME CNRS : Partnership with an academic organisation co-op labs : Academic partnerships final cons. : Firm supplies goods and services to the final consumer cosm ou veto : The targeted sector of the firm is veterinary products or cosmetic products Number of employees between 10 and 50 : Number of employees between 10 and 50 Number of employees less than 10 : Number of employees less than 10 Number of employees up to 50: Number of employees up to 50 INRA : Partnership with an academic organisation dedicated to agronomic and agro-food research INSERM : Partnership with an academic organisation dedicated to medical research Pharma : The targeted sector is human health and pharmaceutical products Product : The firm sells products rather than services 
